Tuberculosis and Respiratory Diseases

  • 제78권3호
  • /
  • Pages.161-167
  • /
  • 2015
  • /
  • 1738-3536(pISSN)
  • /
  • 2005-6184(eISSN)
대한결핵및호흡기학회 (The Korean Academy of Tuberculosis and Respiratory Diseases)
권호 표지
DOI QR코드

DOI QR Code

Treatment of Drug Susceptible Pulmonary Tuberculosis

  • Shin, Hong-Joon (Department of Internal Medicine, Chonnam National University Hospital) ;
  • Kwon, Yong-Soo (Department of Internal Medicine, Chonnam National University Hospital)
  • 투고 : 2015.03.03
  • 심사 : 2015.03.31
  • 발행 : 2015.04.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Tuberculosis (TB) remains a major global health problem, and the incidence of TB cases has not significantly decreased over the past decade in Korea. The standard short course regimen is highly effective against TB, but requires multiple TB-specific drugs and a long treatment duration. Recent studies using late-generation fluoroquinolones and/or high-dose rifapentine-containing regimens to shorten the duration of TB treatment showed negative results. Extending the treatment duration may be considered in patients with cavitation on the initial chest radiograph and positivity in sputum culture at 2 months of treatment for preventing TB relapse. Current evidence does not support the use of fixed-dose combinations compared to separate drugs for the purpose of improving treatment outcomes. All patients receiving TB treatment should be monitored regularly for response to therapy, facilitation of treatment completion, and management of adverse drug reactions. Mild adverse effects can be managed with symptomatic therapy and changing the timing of the drug administration, but severe adverse effects require a discontinuation of the offending drugs.

키워드

참고문헌

  1. World Health Organization. Global tuberculosis report 2014 [Internet]. Geneva: World Health Organization; 2014 [cited 2014 Mar 1]. Available from: http://apps.who.int/iris/bitstream/10665/137094/1/9789241564809_eng.pdf.
  2. Hong YP, Kim SJ, Lew WJ, Lee EK, Han YC. The seventh nationwide tuberculosis prevalence survey in Korea, 1995. Int J Tuberc Lung Dis 1998;2:27-36.
  3. Park YK, Park YS, Na KI, Cho EH, Shin SS, Kim HJ. Increased tuberculosis burden due to demographic transition in Korea from 2001 to 2010. Tuberc Respir Dis 2013;74:104-10. https://doi.org/10.4046/trd.2013.74.3.104
  4. Korea Centers for Disease Control and Prevention. Annual report on the notified tuberculosis patients in Korea 2012 [Internet]. Cheongwon: Korea Centers for Disease Control and Prevention; 2013 [cited 2014 Mar 1]. Available from: http://tbfree.cdc.go.kr/tbfree/cmm/BoardList.do?boardType=REPORT&id=4500.
  5. Park YS, Hong SJ, Boo YK, Hwang ES, Kim HJ, Cho SH, et al. The national status of tuberculosis using nationwide medical records survey of patients with tuberculosis in Korea. Tuberc Respir Dis 2012;73:48-55. https://doi.org/10.4046/trd.2012.73.1.48
  6. Kim HJ. Current status of tuberculosis in Korea. Korean J Med 2012;82:257-62. https://doi.org/10.3904/kjm.2012.82.3.257
  7. Statistics Korea. Annual report of deaths by cause 2012 [Internet]. Daejeon: Statistics Korea; 2013 [cited 2014 Mar 1]. Available from: http://kosis.kr/ups/ups_01List01.jsp?grp_no=1005&pubcode=YD&type=F.
  8. Kwon YS, Kim YH, Song JU, Jeon K, Song J, Ryu YJ, et al. Risk factors for death during pulmonary tuberculosis treatment in Korea: a multicenter retrospective cohort study. J Korean Med Sci 2014;29:1226-31. https://doi.org/10.3346/jkms.2014.29.9.1226
  9. Zumla A, Raviglione M, Hafner R, von Reyn CF. Tuberculosis. N Engl J Med 2013;368:745-55. https://doi.org/10.1056/NEJMra1200894
  10. Joint Committee for the Revision of Korean Guidelines for Tuberculosis, Korea Centers for Disease Control and Prevention. Korean guidelines for tuberculosis. 2nd ed. Seoul and Cheongwon: Joint Committee for the Revision of Korean Guidelines for Tuberculosis, Korean Centers for Disease Control and Prevention; 2014.
  11. Kwon YS, Jeong BH, Koh WJ. Tuberculosis: clinical trials and new drug regimens. Curr Opin Pulm Med 2014;20:280-6. https://doi.org/10.1097/MCP.0000000000000045
  12. Gillespie SH, Crook AM, McHugh TD, Mendel CM, Meredith SK, Murray SR, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 2014;371:1577-87. https://doi.org/10.1056/NEJMoa1407426
  13. Jindani A, Harrison TS, Nunn AJ, Phillips PP, Churchyard GJ, Charalambous S, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med 2014;371:1599-608. https://doi.org/10.1056/NEJMoa1314210
  14. Merle CS, Fielding K, Sow OB, Gninafon M, Lo MB, Mthiyane T, et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med 2014;371:1588-98. https://doi.org/10.1056/NEJMoa1315817
  15. Lienhardt C, Cook SV, Burgos M, Yorke-Edwards V, Rigouts L, Anyo G, et al. Efficacy and safety of a 4-drug fixed-dose combination regimen compared with separate drugs for treatment of pulmonary tuberculosis: the Study C randomized controlled trial. JAMA 2011;305:1415-23. https://doi.org/10.1001/jama.2011.436
  16. Albanna AS, Smith BM, Cowan D, Menzies D. Fixed-dose combination antituberculosis therapy: a systematic review and meta-analysis. Eur Respir J 2013;42:721-32. https://doi.org/10.1183/09031936.00180612
  17. Jo KW, Yoo JW, Hong Y, Lee JS, Lee SD, Kim WS, et al. Risk factors for 1-year relapse of pulmonary tuberculosis treated with a 6-month daily regimen. Respir Med 2014;108:654-9. https://doi.org/10.1016/j.rmed.2014.01.010
  18. Nunn AJ, Cook SV, Burgos M, Rigouts L, Yorke-Edwards V, Anyo G, et al. Results at 30 months of a randomised trial of FDCs and separate drugs for the treatment of tuberculosis. Int J Tuberc Lung Dis 2014;18:1252-4. https://doi.org/10.5588/ijtld.14.0281
  19. Seon HJ, Kim YI, Lim SC, Kim YH, Kwon YS. Clinical significance of residual lesions in chest computed tomography after anti-tuberculosis treatment. Int J Tuberc Lung Dis 2014;18:341-6. https://doi.org/10.5588/ijtld.13.0565
  20. Shin HJ, Lee HS, Kim YI, Lim SC, Jung JP, Ko YC, et al. Hepatotoxicity of anti-tuberculosis chemotherapy in patients with liver cirrhosis. Int J Tuberc Lung Dis 2014;18:347-51. https://doi.org/10.5588/ijtld.13.0545
  21. Blumberg HM, Burman WJ, Chaisson RE, Daley CL, Etkind SC, Friedman LN, et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003;167:603-62. https://doi.org/10.1164/rccm.167.4.603
  22. Schlossberg D. Tuberculosis and nontuberculosis mycobacterial infections. Washington, DC: ASM Press; 2011.
  23. World Health Organization. Treatment of tuberculosis: guidelines for national programmes. 4th ed. WHO/HTM/TB/2009.420. Geneva: World Health Organization; 2009.
  24. Combs DL, O'Brien RJ, Geiter LJ. USPHS Tuberculosis Short-Course Chemotherapy Trial 21: effectiveness, toxicity, and acceptability. The report of final results. Ann Intern Med 1990;112:397-406. https://doi.org/10.7326/0003-4819-76-3-112-6-397
  25. Chang KC, Leung CC, Yew WW, Ho SC, Tam CM. A nested case-control study on treatment-related risk factors for early relapse of tuberculosis. Am J Respir Crit Care Med 2004;170:1124-30. https://doi.org/10.1164/rccm.200407-905OC
  26. Johnson JL, Hadad DJ, Dietze R, Maciel EL, Sewali B, Gitta P, et al. Shortening treatment in adults with noncavitary tuberculosis and 2-month culture conversion. Am J Respir Crit Care Med 2009;180:558-63. https://doi.org/10.1164/rccm.200904-0536OC
  27. Cuneo WD, Snider DE Jr. Enhancing patient compliance with tuberculosis therapy. Clin Chest Med 1989;10:375-80.
  28. The promise and reality of fixed-dose combinations with rifampicin. A joint statement of the International Union Against Tuberculosis and Lung Disease and the Tuberculosis Programme of the World Health Organization. Tuber Lung Dis 1994;75:180-1. https://doi.org/10.1016/0962-8479(94)90004-3
  29. Blomberg B, Spinaci S, Fourie B, Laing R. The rationale for recommending fixed-dose combination tablets for treatment of tuberculosis. Bull World Health Organ 2001;79:61-8.
  30. Milan-Segovia RC, Dominguez-Ramirez AM, Jung-Cook H, Magana-Aquino M, Romero-Mendez MC, Medellin-Garibay SE, et al. Relative bioavailability of rifampicin in a three-drug fixed-dose combination formulation. Int J Tuberc Lung Dis 2010;14:1454-60.
  31. Im JG, Itoh H, Shim YS, Lee JH, Ahn J, Han MC, et al. Pulmonary tuberculosis: CT findings--early active disease and sequential change with antituberculous therapy. Radiology 1993;186:653-60. https://doi.org/10.1148/radiology.186.3.8430169
  32. Kim WS, Moon WK, Kim IO, Lee HJ, Im JG, Yeon KM, et al. Pulmonary tuberculosis in children: evaluation with CT. AJR Am J Roentgenol 1997;168:1005-9. https://doi.org/10.2214/ajr.168.4.9124105
  33. McGuinness G, Naidich DP, Jagirdar J, Leitman B, McCauley DI. High resolution CT findings in miliary lung disease. J Comput Assist Tomogr 1992;16:384-90. https://doi.org/10.1097/00004728-199205000-00009
  34. Pastores SM, Naidich DP, Aranda CP, McGuinnes G, Rom WN. Intrathoracic adenopathy associated with pulmonary tuberculosis in patients with human immunodeficiency virus infection. Chest 1993;103:1433-7. https://doi.org/10.1378/chest.103.5.1433
  35. Hulnick DH, Naidich DP, McCauley DI. Pleural tuberculosis evaluated by computed tomography. Radiology 1983;149:759-65. https://doi.org/10.1148/radiology.149.3.6647852
  36. Lee JJ, Chong PY, Lin CB, Hsu AH, Lee CC. High resolution chest CT in patients with pulmonary tuberculosis: characteristic findings before and after antituberculous therapy. Eur J Radiol 2008;67:100-4. https://doi.org/10.1016/j.ejrad.2007.07.009
  37. World Health Organization. Definitions and reporting framework for tuberculosis, 2013 revision: WHO/HTM/TB/2013.2 [Internet]. Geneva: World Health Organization; 2013 [cited 2015 Mar 3]. Available from: http://apps.who.int/iris/bitstream/10665/79199/1/9789241505345_eng.pdf.
  38. Saukkonen JJ, Cohn DL, Jasmer RM, Schenker S, Jereb JA, Nolan CM, et al. An official ATS statement: hepatotoxicity of antituberculosis therapy. Am J Respir Crit Care Med 2006;174:935-52. https://doi.org/10.1164/rccm.200510-1666ST
  39. Kang YA. Tuberculosis treatment in patients with comorbidities. Tuberc Respir Dis 2014;76:257-60. https://doi.org/10.4046/trd.2014.76.6.257
  40. Lee BH, Koh WJ, Choi MS, Suh GY, Chung MP, Kim H, et al. Inactive hepatitis B surface antigen carrier state and hepatotoxicity during antituberculosis chemotherapy. Chest 2005;127:1304-11. https://doi.org/10.1378/chest.127.4.1304
  41. Kwon YS, Koh WJ, Suh GY, Chung MP, Kim H, Kwon OJ. Hepatitis C virus infection and hepatotoxicity during antituberculosis chemotherapy. Chest 2007;131:803-8. https://doi.org/10.1378/chest.06-2042

피인용 문헌

  1. Active transforming growth factor-β is associated with phenotypic changes in granulomas after drug treatment in pulmonary tuberculosis vol.9, pp.None, 2015, https://doi.org/10.1186/s13069-016-0043-3
  2. New Players in Immunity to Tuberculosis: The Host Microbiome, Lung Epithelium, and Innate Immune Cells vol.9, pp.None, 2015, https://doi.org/10.3389/fimmu.2018.00709
  3. Association of FAM65B, AGBL4, and CUX2 genetic polymorphisms with susceptibility to antituberculosis drug-induced hepatotoxicity : validation study in a Chinese Han population vol.29, pp.4, 2015, https://doi.org/10.1097/fpc.0000000000000370
  4. Inhibitors of energy metabolism interfere with antibiotic-induced death in mycobacteria vol.294, pp.6, 2015, https://doi.org/10.1074/jbc.ra118.005732
  5. Early Discontinuation of Ethambutol in Pulmonary Tuberculosis Treatment Based on Results of the GenoType MTBDRplus Assay: a Prospective, Multicenter, Noninferiority Randomized Trial in South Korea vol.63, pp.12, 2015, https://doi.org/10.1128/aac.00980-19
  6. Impact of the change in the antitubercular regimen from three to four drugs on cure and frequency of adverse reactions in tuberculosis patients from Brazil: A retrospective cohort study vol.14, pp.12, 2015, https://doi.org/10.1371/journal.pone.0227101
  7. Multidrug-resistant tuberculosis risk factors assessment with intuitionistic fuzzy cognitive maps vol.38, pp.1, 2015, https://doi.org/10.3233/jifs-179470
  8. Oral anti-tuberculosis drugs: An urgent medication reconciliation at hospitals in Indonesia vol.10, pp.3, 2015, https://doi.org/10.4081/jphr.2021.1896
  9. Nitric Oxide-Dependent Electron Transport Chain Inhibition by the Cytochrome bc1 Inhibitor and Pretomanid Combination Kills Mycobacterium tuberculosis vol.65, pp.9, 2015, https://doi.org/10.1128/aac.00956-21
  10. Recent Advances in Drug Susceptible Pulmonary Tuberculosis Diagnosis and Treatment vol.96, pp.5, 2015, https://doi.org/10.3904/kjm.2021.96.5.390